All AbMole products are for research use only, cannot be used for human consumption.
RS 504393 is a highly selective CCR2 chemokine receptor antagonist, with IC50 values of 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors, respectively. RS 504393 inhibits MCP-1 chemotaxis (IC50 = 330 nM) and ischemia-reperfusion injury in kidneys.
Int Immunopharmacol. 2021 Oct;99:107947.
The roles of MCP-1/CCR2 mediated macrophage recruitment and polarization in bladder outlet obstruction (BOO) induced bladder remodeling
RS 504393 purchased from AbMole
| Molecular Weight | 417.5 |
| Formula | C25H27N3O3 |
| CAS Number | 300816-15-3 |
| Solubility (25°C) | DMSO ≥ 5 mg/mL (May need ultrasonic) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[4] Kiyoki Kitagawa, et al. Am J Pathol. Blockade of CCR2 ameliorates progressive fibrosis in kidney
| Related CCR Products |
|---|
| Maraviroc
Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacological properties. |
| Vicriviroc Malate
Vicriviroc (SCH 417690) is a pyrimidine CCR5 entry inhibitor of HIV-1 with IC50 of 0.91 nM. |
| Bindarit
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. Bindarit also has anti-inflammatory activity. |
| BMS-813160
BMS-813160 is the first dual CCR2/CCR5 antagonist. BMS-813160 binds with CCR2, CCR5, CCR1, CCR4 and CXCR2 with IC50s of 6.2 nM, 3.6 nM, ＞25 μM, ＞40 μM and ＞40 μM, respectively. |
| INCB3284 dimesylate
INCB 3284 dimesylate is a potent, selective and orally bioavailable hCCR2 antagonist with IC50 of 3.7 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
